DK0578774T3 - Monoklonale antistoffer mod stamcellefaktor-receptorer - Google Patents

Monoklonale antistoffer mod stamcellefaktor-receptorer

Info

Publication number
DK0578774T3
DK0578774T3 DK92910836T DK92910836T DK0578774T3 DK 0578774 T3 DK0578774 T3 DK 0578774T3 DK 92910836 T DK92910836 T DK 92910836T DK 92910836 T DK92910836 T DK 92910836T DK 0578774 T3 DK0578774 T3 DK 0578774T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
stem cell
cell factor
antibodies against
factor receptors
Prior art date
Application number
DK92910836T
Other languages
English (en)
Inventor
Nancy Lin
Virginia C Broudy
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of DK0578774T3 publication Critical patent/DK0578774T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK92910836T 1991-04-05 1992-04-03 Monoklonale antistoffer mod stamcellefaktor-receptorer DK0578774T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68124591A 1991-04-05 1991-04-05
PCT/US1992/002674 WO1992017505A1 (en) 1991-04-05 1992-04-03 Monoclonal antibodies to stem cell factor receptors

Publications (1)

Publication Number Publication Date
DK0578774T3 true DK0578774T3 (da) 1999-04-26

Family

ID=24734435

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92910836T DK0578774T3 (da) 1991-04-05 1992-04-03 Monoklonale antistoffer mod stamcellefaktor-receptorer

Country Status (10)

Country Link
US (5) US5489516A (da)
EP (1) EP0578774B1 (da)
JP (1) JP3213314B2 (da)
AT (1) ATE169031T1 (da)
CA (1) CA2107553C (da)
DE (1) DE69226431T2 (da)
DK (1) DK0578774T3 (da)
ES (1) ES2118820T3 (da)
HK (1) HK1008827A1 (da)
WO (1) WO1992017505A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005795A1 (en) * 1989-10-16 1991-05-02 Amgen Inc. Stem cell factor
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
ES2118820T3 (es) * 1991-04-05 1998-10-01 Univ Washington Anticuerpos monoclonales para receptores de factores de celulas pluripotentes.
EP0548867A2 (en) * 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
US5911988A (en) * 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
DE19600589C1 (de) * 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
AU5159798A (en) * 1996-11-05 1998-05-29 Bristol-Myers Squibb Company Branched peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
SE511939C2 (sv) * 1998-10-29 1999-12-20 Henrik Willers Förfarande och anordning för förankring av en boj
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
CA2402081C (en) 2000-03-06 2015-09-22 University Of Kentucky Research Foundation A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells
US20050064587A1 (en) * 2001-09-07 2005-03-24 Lawrence Rosenberg Pancreatic small cells and uses thereof
US20030175818A1 (en) * 2002-03-15 2003-09-18 Ross Amelia A. Devices and methods for isolating and recovering target cells
US7754155B2 (en) * 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003241313A1 (en) * 2002-04-23 2003-11-10 Roger Williams Hospital Compositions and methods for stem cell delivery
AU2003289116A1 (en) * 2002-12-16 2004-07-09 Canon Kabushiki Kaisha Pattern identification method, device thereof, and program thereof
WO2005067889A1 (en) 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CA2698583A1 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
WO2008067115A2 (en) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
EP3241558B1 (en) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
EP3381943B1 (en) 2012-07-25 2022-03-16 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
AP2015008656A0 (en) 2013-03-15 2015-08-31 Novartis Ag Antibody drug conjugates
WO2015050959A1 (en) * 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
CA2980748A1 (en) 2015-03-25 2016-09-29 Children's Hospital Medical Center Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP7062647B2 (ja) 2016-06-17 2022-05-06 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
SG11201906319XA (en) 2017-01-20 2019-08-27 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
AU2022409748A1 (en) 2021-12-16 2024-05-23 Cimeio Therapeutics Ag Discernible cell surface protein variants of cd117 for use in cell therapy
WO2024008910A1 (en) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5081030A (en) * 1989-04-25 1992-01-14 The Johns Hopkins University Release of cells from affinity matrices
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
ES2118820T3 (es) * 1991-04-05 1998-10-01 Univ Washington Anticuerpos monoclonales para receptores de factores de celulas pluripotentes.

Also Published As

Publication number Publication date
CA2107553A1 (en) 1992-10-06
US5919911A (en) 1999-07-06
JP3213314B2 (ja) 2001-10-02
EP0578774B1 (en) 1998-07-29
US5922847A (en) 1999-07-13
WO1992017505A1 (en) 1992-10-15
CA2107553C (en) 2001-07-31
DE69226431D1 (de) 1998-09-03
EP0578774A4 (en) 1995-11-15
US5489516A (en) 1996-02-06
JPH06506833A (ja) 1994-08-04
EP0578774A1 (en) 1994-01-19
HK1008827A1 (en) 1999-05-21
DE69226431T2 (de) 1999-04-22
ATE169031T1 (de) 1998-08-15
US5906938A (en) 1999-05-25
US20020018775A1 (en) 2002-02-14
ES2118820T3 (es) 1998-10-01

Similar Documents

Publication Publication Date Title
DK0578774T3 (da) Monoklonale antistoffer mod stamcellefaktor-receptorer
DK0817847T4 (da) IL-17-receptor
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
MY122262A (en) Lh-rh peptide analogues their uses and pharmaceutical compositions containing them
DE69824029D1 (de) Bicyclische kinase inhibitoren
BG102172A (en) New stable medicamentous compositions for the preparation of propellant-free aerosols
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
IL141082A0 (en) Peptide antagonists of zonulin and pharmaceutical compositions containing the same
IL122370A (en) Monkey monoclonal antibodies to human B7 antigens and pharmaceutical compositions containing them
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
IL103510A0 (en) Pharmaceutical compositions containing antibodies for causing immunosuppression
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
ES8704946A1 (es) Un procedimiento para la preparacion de triazolobenzodiazefinas.
YU394A (sh) Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu
FI941457A0 (fi) Verihiutaleglyproteiini IIb/IIIa:n inhibiittoreina käyttökelpoisia syklisiä yhdisteitä
ATE248190T1 (de) Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen
EP1491632A3 (en) Anti-alphavbeta3 humanized monoclonal antibodies
RU94022277A (ru) Новые 19-норстероиды, имеющие в положении 11 - бета феноксиалкилсульфонамидную или феноксиалкилсульфонилкарбамидную цепь, метод и промежуточные продукты их получения, и содержащая их фармацевтическая композиция
YU13392A (sh) ANTITELA NA HUMANI RECEPTOR ZA IgE
NZ337601A (en) Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics by inhibiting IgE expression
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
DE59105603D1 (de) Monoklonale antikörper gegen den interleukin 2-rezeptor.
ATE207935T1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
MD553F1 (en) New derivatives of pyrazolepyrimidine receptors antagonists of angiotensine II, realization processes and pharmaceutical compositions